Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | JAK2 | O60674 | 5/20 | 0.58 |
| ▸ | JAK3 | P52333 | 5/20 | 0.58 |
| ▸ | JAK1 | P23458 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 4/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | FER | P16591 | 2/20 | 0.47 |
| ▸ | BLK | P51451 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19492067 | 1.00 | RET (0.60) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL21292738 | 0.89 | JAK3 (0.60) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL21292635 | 0.89 | JAK3 (0.60) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL18642030 | 0.83 | JAK2 (0.65) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19492063 | 0.82 | RET (0.62) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19492064 | 0.82 | RET (0.62) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19492062 | 0.82 | RET (0.62) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19492070 | 0.78 | JAK2 (0.60) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19492066 | 0.78 | JAK2 (0.60) | RETKDRJAK2JAK3JAK1 | |
| SCHEMBL19476921 | 0.78 | JAK2 (0.62) | RETKDRJAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| EP-4104837-A2 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| EP-4104837-A2 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| EP-3442535-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20210047334-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10844067-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20190263819-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| WO-2017178845-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885JAK2 59/4885 |
| US-20190263819-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885JAK2 59/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885JAK2 59/4885 |
| US-20210047334-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885JAK2 59/4885 |
| US-10844067-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885JAK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.